Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.91 Average PT from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $38.91.

Several analysts have commented on DNLI shares. Cantor Fitzgerald downgraded shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. Jefferies Financial Group raised their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday. William Blair assumed coverage on Denali Therapeutics in a research note on Friday, January 3rd. They issued an "outperform" rating on the stock. Finally, HC Wainwright cut their price target on Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating on the stock in a report on Tuesday.

Denali Therapeutics Price Performance

DNLI traded down $2.17 during mid-day trading on Friday, hitting $19.08. The stock had a trading volume of 500,919 shares, compared to its average volume of 1,054,178. The stock's fifty day simple moving average is $24.13 and its 200-day simple moving average is $24.83. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -6.91 and a beta of 1.39. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the company posted ($0.72) earnings per share. As a group, research analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This represents a 0.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 14.50 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 104,518 shares of company stock worth $2,576,982. Corporate insiders own 7.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in Denali Therapeutics by 13.3% during the second quarter. Rhumbline Advisers now owns 194,859 shares of the company's stock worth $4,525,000 after buying an additional 22,900 shares during the last quarter. TD Asset Management Inc grew its holdings in Denali Therapeutics by 4.5% in the second quarter. TD Asset Management Inc now owns 179,152 shares of the company's stock worth $4,160,000 after purchasing an additional 7,766 shares during the period. Arizona State Retirement System raised its holdings in shares of Denali Therapeutics by 9.0% during the second quarter. Arizona State Retirement System now owns 33,114 shares of the company's stock valued at $769,000 after purchasing an additional 2,730 shares during the period. American Century Companies Inc. boosted its position in shares of Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company's stock worth $12,135,000 after purchasing an additional 63,058 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Denali Therapeutics by 6.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock valued at $32,913,000 after buying an additional 84,522 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.